Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NASDAQ:CRDL NASDAQ:IMMX NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$21.97+13.0%$21.08$89.95▼$99.05$636.80M0.9553,591 shs1.41 million shsCRDLCardiol Therapeutics$1.05-0.5%$1.27$0.88▼$1.71$120.43M0.72521,508 shs214,690 shsIMMXImmix Biopharma$9.80-1.1%$9.21$1.94▼$11.61$532.19M0.11.04 million shs521,614 shsRZLTRezolute$5.10+4.4%$3.66$1.07▼$11.46$482.89M0.682.59 million shs1.19 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+15.64%+20.81%-12.43%+46.68%+96.66%CRDLCardiol Therapeutics-0.94%-0.94%-20.45%-1.87%-17.97%IMMXImmix Biopharma+5.43%+13.39%+12.87%+11.22%+344.39%RZLTRezolute-5.05%+7.00%+50.46%+53.77%+21.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$21.97+13.0%$21.08$89.95▼$99.05$636.80M0.9553,591 shs1.41 million shsCRDLCardiol Therapeutics$1.05-0.5%$1.27$0.88▼$1.71$120.43M0.72521,508 shs214,690 shsIMMXImmix Biopharma$9.80-1.1%$9.21$1.94▼$11.61$532.19M0.11.04 million shs521,614 shsRZLTRezolute$5.10+4.4%$3.66$1.07▼$11.46$482.89M0.682.59 million shs1.19 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics+15.64%+20.81%-12.43%+46.68%+96.66%CRDLCardiol Therapeutics-0.94%-0.94%-20.45%-1.87%-17.97%IMMXImmix Biopharma+5.43%+13.39%+12.87%+11.22%+344.39%RZLTRezolute-5.05%+7.00%+50.46%+53.77%+21.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/ACRDLCardiol Therapeutics 2.33Hold$8.50713.40% UpsideIMMXImmix Biopharma 2.67Moderate Buy$20.67110.80% UpsideRZLTRezolute 2.64Moderate Buy$9.3883.68% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, AVTE, RZLT, and IMMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026IMMXImmix Biopharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/18/2026IMMXImmix Biopharma Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.006/17/2026IMMXImmix Biopharma Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$19.006/15/2026RZLTRezolute GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $11.006/3/2026RZLTRezolute Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/3/2026RZLTRezolute CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform6/3/2026RZLTRezolute Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$11.006/3/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.006/2/2026RZLTRezolute BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.006/2/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.006/2/2026RZLTRezolute HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AIMMXImmix BiopharmaN/AN/AN/AN/A$1.77 per shareN/ARZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/ACRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%8/14/2026 (Estimated)RZLTRezolute-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%N/ALatest CRDL, AVTE, RZLT, and IMMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q3 2026RZLTRezolute-$0.1686-$0.16+$0.0086-$0.16N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78CRDLCardiol TherapeuticsN/A4.394.39IMMXImmix BiopharmaN/A8.758.75RZLTRezoluteN/A15.8415.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/ACRDLCardiol Therapeutics12.49%IMMXImmix Biopharma11.26%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%CRDLCardiol Therapeutics5.25%IMMXImmix Biopharma30.30%RZLTRezolute14.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableRZLTRezolute4096.29 million82.06 millionOptionableCRDL, AVTE, RZLT, and IMMX HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Rating Increased to Hold at Wall Street ZenJune 22 at 1:06 AM | americanbankingnews.comRezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine SocietyJune 17, 2026 | globenewswire.comRezolute (NASDAQ:RZLT) Stock Rating Lowered by Wall Street ZenJune 14, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)June 12, 2026 | theglobeandmail.comPositive Signs As Multiple Insiders Buy Rezolute StockJune 10, 2026 | finance.yahoo.comRZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?June 4, 2026 | zacks.comRezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital HyperinsulinismJune 4, 2026 | quiverquant.comQRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine SocietyJune 4, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)June 3, 2026 | theglobeandmail.comRezolute upgraded at Citizens after late-stage trial data for lead assetJune 3, 2026 | seekingalpha.comRezolute rises after late-stage trial updateJune 3, 2026 | msn.comRezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease StudyJune 2, 2026 | benzinga.comRezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismJune 2, 2026 | globenewswire.comRezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comRezolute to Participate in Upcoming Investor ConferencesMay 11, 2026 | globenewswire.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society ...May 1, 2026 | markets.businessinsider.comRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingMay 1, 2026 | globenewswire.comRezolute, Inc. Investigated by the Portnoy Law FirmApril 24, 2026 | globenewswire.comRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual MeetingApril 21, 2026 | globenewswire.comRezolute: Sell Rating Despite FDA Feedback From Type B Meeting For ErsodetugMarch 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDL, AVTE, RZLT, and IMMX Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$21.97 +2.52 (+12.96%) As of 06/23/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Cardiol Therapeutics NASDAQ:CRDL$1.04 -0.01 (-0.48%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Immix Biopharma NASDAQ:IMMX$9.80 -0.11 (-1.07%) As of 02:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Rezolute NASDAQ:RZLT$5.10 +0.21 (+4.38%) As of 02:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
